| Stock Symbol | NASDAQ: NMRA |
|---|
| Headquarters | Boston, Massachusetts, USA |
|---|
| Founded | 2020 |
|---|
| IPO | October 2023 |
|---|
| Market Cap | ~$500M (2025) |
|---|
| Focus | CNS disorders, Precision medicine |
|---|
Neumora Therapeutics is a biotechnology company pioneering a new era of precision medicines to restore brain health and wellbeing. Founded in 2020 and headquartered in Boston, Massachusetts, Neumora focuses on developing novel therapeutics for central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, depression, and anxiety.
The company distinguishes itself through its precision medicine approach, targeting therapeutically relevant mechanisms implicated in CNS diseases with best-in-class pharmacology. Neumora's pipeline leverages deep understanding of disease biology to develop treatments that address underlying pathology rather than just symptoms.
Neumora launched with one of the largest biotech Series A financings in history at $500 million in 2021, reflecting significant investor confidence in its approach. The company went public in October 2023, raising approximately $250 million in its IPO.
¶ Founding and Early Development (2020-2022)
Neumora Therapeutics was founded in 2020 by a team of neuroscience experts and pharmaceutical industry veterans with a vision to transform CNS drug development. The company's formation was based on several years of research identifying novel therapeutic targets and developing proprietary drug discovery capabilities.
Key aspects of the founding period:
- Experienced leadership: CEO and founding team with backgrounds at leading pharmaceutical companies and biotech firms
- Novel target identification: Focus on under-explored mechanisms in CNS disorders
- Precision medicine focus: Emphasis on biomarker-driven development and patient selection
The company's name "Neumora" reflects its mission to restore brain health, combining "neuro" with the concept of "more" — indicating the company's ambition to unlock additional therapeutic potential in the brain.
¶ Series A and Pipeline Development (2021-2022)
In 2021, Neumora completed a landmark $500 million Series A financing, one of the largest biotech Series A rounds ever. This funding enabled:
- Advancement of lead programs through preclinical development
- Expansion of discovery capabilities
- Building of clinical development infrastructure
- Strategic partnership discussions
The financing was led by ARCH Venture Partners with participation from other prominent investors including Andreessen Horowitz, Polaris Partners, and Third Kind Ventures.
¶ IPO and Public Company Period (2023-Present)
Neumora went public in October 2023, completing an initial public offering on NASDAQ that raised approximately $250 million. The IPO reflected strong investor interest in the company's differentiated approach to CNS drug development.
As a public company, Neumora has:
- Initiated clinical development of lead programs
- Expanded clinical operations capabilities
- Advanced additional pipeline programs
- Established strategic partnerships with larger pharmaceutical companies
¶ Technology and Approach
Neumora's approach is built on precision medicine principles that aim to match the right drug with the right patient population:
Key Elements:
- Target validation: Rigorous validation of therapeutic targets using human data and biomarkers
- Patient selection: Identification of patient subpopulations most likely to respond to treatment
- Mechanism-based design: Drugs designed to specifically modulate validated disease mechanisms
- Biomarker integration: Biomarkers used throughout development for dose selection and patient stratification
This approach addresses a major challenge in CNS drug development — the historically high failure rate due to inadequate target validation and patient selection.
Neumora built internal drug discovery capabilities to support its pipeline:
- Medicinal chemistry: Optimization of lead compounds for potency, selectivity, and drug-like properties
- Pharmacology: In vitro and in vivo characterization of mechanism and efficacy
- DMPK: Assessment of absorption, distribution, metabolism, and excretion properties
- Safety: Early identification and mitigation of safety liabilities
The company has developed a clinical development strategy emphasizing:
- Proof-of-concept studies: Rapid evaluation of target engagement and early efficacy signals
- Biomarker incorporation: Integration of biomarkers from early development
- Regulatory engagement: Proactive interactions with regulatory agencies
- Patient engagement: Collaboration with patient advocacy groups and clinical sites
Lead Program for Depression and Related Conditions
NMRA-140 is a potent and selective kappa opioid receptor (KOR) antagonist being developed for major depressive disorder (MDD) and related conditions including bipolar depression and treatment-resistant depression.
The kappa opioid receptor system plays a critical role in stress response and mood regulation:
- Dynorphin: The endogenous ligand for KOR, released during stress
- KOR activation: Leads to dysphoria, anxiety, and stress response
- KOR antagonists: Block the effects of dynorphin, potentially alleviating depression
Research has demonstrated that KOR antagonism can produce antidepressant and anxiolytic effects in preclinical models. The role of the dynorphin/KOR system in stress-induced behaviors makes it a compelling target for depression.
NMRA-140 has completed Phase 1 clinical studies demonstrating:
- Safety and tolerability: Favorable safety profile in healthy volunteers
- Pharmacokinetics: Suitable exposure for once-daily dosing
- Target engagement: Evidence of KOR occupancy at therapeutic doses
The program is advancing to Phase 2 studies in major depressive disorder.
Depression represents a significant unmet medical need:
- Prevalence: Over 280 million people globally have depression
- Treatment gaps: Approximately one-third of patients do not respond to existing treatments
- Novel mechanisms: There have been few new mechanisms approved for depression in decades
NMRA-140 represents a novel mechanism with potential to address unmet need in treatment-resistant depression.
Program for Neuropsychiatric Symptoms in Neurodegeneration
NMRA-511 is a phosphodiesterase 10A (PDE10A) inhibitor targeting neuropsychiatric symptoms in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
PDE10A is highly expressed in striatal medium spiny neurons (MSNs), where it regulates cyclic adenosine monophosphate (cAMP) signaling critical for motor control and reward processing:
- PDE10A function: Hydrolyzes cAMP and cGMP, terminating intracellular signaling
- PDE10A inhibition: Increases cAMP levels, modulating neuronal activity
- Therapeutic potential: Affects motor function, cognition, and behavior
In neurodegenerative diseases, PDE10A expression and function are altered, contributing to both motor and non-motor symptoms.
In Alzheimer's disease, PDE10A inhibition may address:
- Cognitive function: cAMP signaling is important for learning and memory processes
- Psychiatric symptoms: Agitation, anxiety, and depression are common in AD
- Motor function: Some AD patients develop extrapyramidal symptoms
In Parkinson's disease, PDE10A targeting may:
- Motor symptoms: Modulation of striatal circuitry may improve motor function
- Non-motor symptoms: Depression, anxiety, and cognitive impairment
- Levodopa-induced dyskinesias: Potential to reduce dyskinesia severity
NMRA-511 is in preclinical development with IND-enabling studies underway.
Neumora has additional programs in various stages of discovery and development:
| Program |
Target |
Indication |
Stage |
| NMRA-094 |
Various |
Substance use disorders |
Discovery |
| NMRA-XXX |
Novel target |
Depression |
Research |
| NMRA-YYY |
Neuroimmune |
Alzheimer's disease |
Research |
The company continues to expand its pipeline through both internal discovery and external partnerships.
Neumora has established a strategic collaboration with Pfizer for co-development of select programs. The partnership provides:
- Development expertise: Pfizer's global clinical development capabilities
- Commercial infrastructure: Established marketing and distribution networks
- Additional capital: Funding support for development programs
- Strategic guidance: Access to Pfizer's scientific and regulatory expertise
Through Amgen's acquisition of Arena Pharmaceuticals, Neumora gained access to additional infrastructure and expertise. Arena's portfolio of immunology and oncology programs complements Neumora's CNS focus, and the combined company has access to:
- Clinical operations: Global clinical trial capabilities
- Manufacturing: Scale-up and commercial manufacturing
- Regulatory: Established regulatory affairs functions
The kappa opioid receptor is one of three classical opioid receptors (mu, delta, kappa) with distinct pharmacological and physiological properties:
KOR Signaling:
- G-protein coupled receptor: Primarily couples to Gi/o proteins
- Signal transduction: Inhibits adenylate cyclase, reduces cAMP
- Beta-arrestin pathways: Additional signaling through beta-arrestin recruitment
KOR and Mood:
- Stress increases dynorphin release
- KOR activation produces dysphoric and anxiogenic effects
- KOR antagonists block these effects in preclinical models
Clinical Evidence:
- Early KOR antagonists showed antidepressant effects but had limitations
- Next-generation KOR antagonists aim for improved selectivity and drug-like properties
Phosphodiesterase 10A is a dual-specificity phosphodiesterase with high expression in striatal neurons:
Expression Patterns:
- Highest expression in striatum (caudate and putamen)
- Moderate expression in other brain regions
- Cell-type specific expression in medium spiny neurons
Therapeutic Implications:
- PDE10A inhibitors increase cAMP in striatal neurons
- Modulation affects motor control, reward processing, and cognition
- Potential applications in movement disorders and psychiatric conditions
Neumora incorporates biomarkers throughout its clinical development:
Types of Biomarkers:
- Target engagement: Measures of receptor occupancy or pathway modulation
- Pharmacodynamic: Biomarkers reflecting drug effect on disease biology
- Predictive: Markers identifying patients likely to respond to treatment
- Safety: Biomarkers monitoring for potential adverse effects
Implementation:
- Early-phase studies include biomarker endpoints
- Phase 2 studies enriched with biomarker-selected patients
- Regulatory interactions focused on biomarker qualification
Precision medicine requires identifying patient populations most likely to benefit:
- Genetic markers: Where applicable, genetic tests for patient stratification
- Clinical characteristics: Phenotypic features predicting response
- Biomarker thresholds: Measurable thresholds for patient inclusion
Neumora works proactively with regulatory agencies:
- Fast Track: For serious conditions with unmet need
- Breakthrough Therapy: For significant clinical improvement potential
- Adaptive trials: Innovative trial designs for efficient development
¶ Competitive Landscape
Neumora operates in a competitive space for CNS drug development:
| Company |
Mechanism |
Lead Program |
Status |
| Neumora |
KOR antagonist |
NMRA-140 |
Phase 2 |
| BMS |
KOR antagonist |
BMS-986020 |
Phase 2 |
| AbbVie |
KOR antagonist |
Aticaprant |
Phase 3 |
| Intra-Cellular |
PDE10A |
ITI-642 |
Phase 2 |
| Neurocrine |
Various |
Multiple programs |
Various |
Neumora differentiates itself through:
- Novel mechanisms: KOR and PDE10A represent underexplored targets
- Precision approach: Biomarker-driven development
- First-mover potential: Lead programs in early-to-mid development
- Strong financing: Substantial capital to advance programs
| Event |
Year |
Amount |
| Series A |
2021 |
$500M |
| Series B |
2022 |
$75M |
| IPO |
2023 |
$250M |
| Secondary |
2024 |
$50M |
Neumora allocates resources across its portfolio:
- NMRA-140: Largest investment, Phase 2 preparation
- NMRA-511: Significant investment, IND-enabling
- Discovery: Continued investment in early pipeline
¶ Challenges and Considerations
Developing CNS drugs presents inherent challenges:
- BBB penetration: Ensuring adequate brain exposure
- Clinical endpoints: Measuring subjective symptoms reliably
- Placebo effects: High placebo response in psychiatric trials
- Long-term safety: Required for chronic treatments
The CNS space is competitive:
- Large pharma: Major companies with substantial CNS portfolios
- Emerging biotech: Multiple companies pursuing similar mechanisms
- Academic groups: Research institutions developing novel approaches
CNS drug approval requires:
- Demonstration of efficacy: Clear evidence of clinical benefit
- Safety profile: Understanding of risks and benefits
- Manufacturing quality: Consistent product quality
- Complete Phase 2 studies for NMRA-140 in depression
- File IND for NMRA-511 in Alzheimer's/Parkinson's
- Advance discovery programs toward preclinical development
- Expand partnerships for co-development and commercialization
Neumora's vision includes:
- Multiple CNS franchises: Building breadth across CNS disorders
- Precision medicine leader: Demonstrating value of biomarker approach
- Commercial capabilities: Preparing for potential product launches
- Sustained innovation: Continuing to advance novel mechanisms
The company's approach reflects several key insights:
- Unmet need in CNS disorders remains substantial
- Novel mechanisms offer potential for breakthrough therapies
- Precision medicine can improve development success rates
- Strategic partnerships can accelerate and de-risk development
¶ Impact on CNS Treatment Landscape
If successful, NMRA-140 would provide:
- Novel mechanism: First new mechanism for depression in years
- Treatment-resistant option: Options for patients failing existing therapies
- Improved outcomes: Potential for better response rates
PDE10A programs address:
- Symptomatic management: Motor and non-motor symptoms
- Quality of life: Addressing neuropsychiatric manifestations
- Disease modification: Potential disease-modifying approaches
Neumora's success would validate:
- Biomarker-driven development for CNS
- Novel mechanism exploration in well-validated targets
- Efficient clinical development with targeted patient selection